Show simple item record

dc.contributor.authorWetmore, John B
dc.contributor.authorArbelo, José Matías
dc.contributor.authorCatalán, María José
dc.contributor.authorValldeoriola, Francesc
dc.contributor.authorRodriguez-Blazquez, Carmen 
dc.contributor.authorMartínez-Martín, Pablo 
dc.date.accessioned2020-03-18T07:45:27Z
dc.date.available2020-03-18T07:45:27Z
dc.date.issued2019
dc.identifier.citationParkinsons Dis. 2019 Mar 28;2019:1965394.es_ES
dc.identifier.issn2090-8083es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9265
dc.description.abstractObjectives: To assess the psychometric attributes of the Apathy Scale- (AS-) Spanish version in patients with advanced Parkinson's disease (APD). Materials and Methods: Over 6 months, 61 patients participated in a clinical study of levodopa-carbidopa intestinal gel (LCIG) and were evaluated using the AS and other clinical tools. Various psychometric attributes of the AS were assessed. Results: Patients (60.7% men) were aged 68.02 ± 7.43 years, with 12.57 ± 5.97 years from PD diagnosis. Median HY of patients in "on state" was 2 (range, 1-4), and mean levodopa equivalent daily dose was 1455.98 ± 456.00 mg. Overall, the parameters of feasibility/acceptability were satisfactory, except for a moderate-to-high floor effect in AS items but not in its total score (both 3.3%). Cronbach's alpha was 0.78, while item homogeneity coefficient was 0.21. Almost all items (11/14) reached acceptable item-total corrected correlations (rS = 0.16-0.50). AS total score was moderately correlated with Beck Depression Inventory (0.34) and with Non-Motor Symptoms Scale domains 2 (sleep/fatigue, 0.35), 3 (mood/apathy, 0.56), and 5 (attention/memory, 0.41). There were no significant differences between AS total scores by established groups of sex, time from diagnosis, HY, and Clinical Global Impression-Severity Scale. Following LCIG treatment, there was no significant change in the AS total score. The relative change was 5.56%, the standard error of the difference was 4.17, and Cohen's d effect was 0.10. Conclusions: The AS showed satisfactory feasibility, acceptability, scaling assumptions, internal consistency, and convergent validity. Responsiveness parameters were poor, probably due to the characteristics of the clinical study from which these data came. This trial is registered with NCT02289729.es_ES
dc.description.sponsorshipThe study was sponsored by AbbVie S.L.U. The data for the present study are derived from the national, multicenter ADEQUA study. The design, study conduct, and financial support for the ADEQUA study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of this manuscript.es_ES
dc.language.isoenges_ES
dc.publisherHindawi es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titlePsychometric Properties of the Apathy Scale in Advanced Parkinson's Diseasees_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID31031906es_ES
dc.format.volume2019es_ES
dc.format.page1965394es_ES
dc.identifier.doi10.1155/2019/1965394es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.1155/2019/1965394es_ES
dc.identifier.journalParkinson's diseasees_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional